Ashurst advised Jefferies, as sole bookrunner, in relation to an accelerated book build private placement of new shares by Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplants safer and more effective for patients suffering from blood cancers and inherited blood disorders.

Kiadis placed 2,250,000 new shares listed and traded on Euronext Amsterdam and Euronext Brussels with institutional investors for an aggregate amount of €18 million. 

The Ashurst team was led by US securities partner Eric Stuart, together with senior associate Tara Waters, and associate Ciaran Fitzgerald-Morgan.